This will play a video. - Woman walks on the beach holding a scarf over her head.


Your best choice for sacral neuromodulation.


InterStim™ systems have been implanted in over 325,000 patients*, and evaluated in more than 1,000 published clinical articles, including long-term (5-year) data for urinary incontinence, retention, and faecal incontinence.1-3

InterStim Micro systems which include a handheld device and InterStim Micro and InterStim II products for Sacral neuromodulation (SNM) uses mild electrical stimulation of the sacral nerve for bladder and bowel control.


With the InterStim™ systems, the implanted neurostimulator and lead electrically stimulate the sacral nerve. This is thought to normalise neural communication between the bladder and brain and between the bowel and brain.4,5 Unlike oral medications that target the muscular component of bladder control, the InterStim™ systems offer control of symptoms through direct modulation of the nerve activity.4,5

One key advantage of this therapy is that it can be tested for potential success prior to implantation. The evaluation provides an opportunity to find out whether adequate symptom reduction is achieved. Complications can occur with the evaluation, including tissue damage, infection, and technical problems with the device. Patients should be instructed on operating the programmer and given precautions related to the evaluation.

The most common adverse events experienced during clinical studies of patients with SNM included pain at implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations. Any of these may require additional surgery or cause the return of symptoms.


  • Not all patients with bladder control problems benefit from standard medical therapy6,9
  • Standard pharmacological therapy for OAB consists of anticholinergics or β3- adrenoreceptor agonists, which are not effective for everyone10
  • More than 70% of patients stop taking OAB medications within six months due to side effects and/or lack of efficacy6
  • The InterStim™ II system can provide effective bladder control for patients who do not find relief from initial treatments1,9 and the InterStim™ Micro system is designed to deliver the same results



  • Not all patients with bowel control problems benefit from medication, diet modification, and exercise10
  • The InterStim™ systems offer a minimally invasive option that can restore bowel function
  • The InterStim™ II system is effective, safe, and may offer patients improved quality of life9 and the InterStim™ Micro system is designed to deliver the same results



See how the evaluation works by watching instructional videos.

Watch Videos


Follow Medtronic Pelvic Health on Twitter for the latest updates on our products and therapies. 


Data from InterStim Sales Analysis. Medtronic, Inc. April 2020.

Restored bladder function defined as ≥50% reduction in dysfunctional voiding symptoms from baseline. Restored bowel function is defined as ≥50% reduction in chronic fecal incontinence episodes.


Siegel, S. et al. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation. J. Urol. 199, 229–236 (2018).


Hull T, Giese C, Wexner SD, Mellgren A, Devroede G, et al. Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence. Dis Colon Rectum. 2013;56:234–245.


van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP et al. Results of sacral neuromodulation therapy for urinary

voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol. 2007 Nov;178(5):2029-34.


Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. Urol Clin North Am. 2005;32:11-18.


Patton V, Wiklendt L, Arkwright JW, Lubowski DZ, Dinning PG. The effect of sacral nerve stimulation on distal colonic motility in patients with fecal incontinence. Br J Surg. 2013;100:959–968.


Yeaw J, Benner J, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):724-736.


Yu, Y. F., Nichol, M. B., Yu, A. P. & Ahn, J. Persistence and Adherence of Medications for Chronic Overactive Bladder/Urinary Incontinence in the California Medicaid Program. Value Heal. 8, 495–505 (2005).


Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. American Urological Association (AUA). J Urol. 2015 May;193(5):1572-80.


Medtronic InterStim Therapy Clinical Summary, 2018.


Matzel K.E. (2017) Fecal Incontinence. In: Herold A., Lehur PA., Matzel K., O’Connell P. (eds) Coloproctology. European Manual of Medicine. Springer, Berlin, Heidelberg. DOI 10.1007/978-3-662-53210-2_9

See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. If using an MRI SureScan® device, see the MRI SureScan® technical manual before performing an MRI. For further information, contact your local Medtronic representative and/or consult the Medtronic website at website 

For applicable products, consult instructions for use on

Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.